• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Trinity Biotech to Announce Q3 2024 Financial Results

    11/14/24 8:07:06 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TRIB alert in real time by email

    DUBLIN, Ireland, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the third quarter 2024 on Friday, November 15, 2024 and host a conference call at 10:00 AM ET.

    Conference Call Dial-In & Webcast Information

    Date:Friday, November 15, 2024
    Time:10:00 AM ET
    United States:1-877-407-0784
    International:1-201-689-8560
    Conference ID:

    Webcast:

    Call me™:
    13750164

    click here

    https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6



    About Trinity Biotech


    Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com



    Contact: Trinity Biotech plc  LifeSci Partners, LLC
     Louise Tallon  Eric Ribner
     (353)-1-2769800(1)-646-751-4363                
      E-mail: [email protected]


    Primary Logo

    Get the next $TRIB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRIB

    DatePrice TargetRatingAnalyst
    More analyst ratings